Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses

Cancer Research

Volumn 58, Issue 18, 1998, Pages 4132-4137

  Koppan, Miklos ^a   Nagy, Attila ^c   Schally, Andrew V ^b   Arencibia, Jose M ^c   Plonowski, Artur ^c   Halmos, Gabor ^c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDINODOXORUBICIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN DERIVATIVE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VAPREOTIDE;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; GROWTH INHIBITION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALE GENITAL TRACT CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; MALE; OCTREOTIDE; PROSTATIC NEOPLASMS; PYRROLES; RATS; RECEPTORS, SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0032530629     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Landis, S. H., Murra, T., Bokten, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Schroder, F. H., and Boyle, P. Screening of prostate cancer: necessity or nonsense? Eur. J. Cancer, 29A: 656-661, 1993.
3. Schally, A. V., and Comaru-Schally, A. M. Hypothalamic and other peptide hormones. In: Holland, J. F., Frei, E., III, Bast, R. C, Jr., Kufe, D. E., Morton, D. L., and Weichselbaum. R. R. (eds.), Cancer Medicine, Ed. 4, pp. 1067-1086. Baltimore: Williams & Wilkins, 1997.
4. Crawford, E. D. Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer, 66 (Suppl. 5): 1035-1038, 1990.
5. Sogani, P. C., and Fair, W. R. Treatment of advanced prostatic cancer. Urol. Clin. North Am., 14: 353-371, 1987.
6. Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin. Oncol., 15: 371-389, 1988.
7. Rangel, C., Matzkin, H., and Solovay, M. S. Experience with weekly doxorubicin (Adriamycin) in hormone-refractory stage D2 prostate cancer. Urology, 39: 577-582, 1992.
8. Reubi, J. C., Krenning, E. P., Lamberts S. W. J., and Kvols, L. In vitro detection of somatostatin receptors in human tumors. Metabolism, 41 (Suppl. 2): 104-110, 1992.
9. Sinisi, A. A., Bellastella, A., Prezioso, D., Nicchio, M. R., Lotti, T., Salvatore, M., and Pasquali, D. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J. Clin. Endocrinol. Metab., 82: 2566-2569, 1997.
10. Munkelewitz, R. A., Whyard, T. C., Waltzer, W. C., Meek, A. G., and Hod, Y. Expression of somatostatin receptors in human prostatic cell lines. J. Urol., 157 (Suppl. 4): 9, 1997.
11. Brevini, T. A., Bianchi, R., and Motta, M. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J. Clin. Endocrinol. Metab., 77: 626-631, 1993.
12. Taylor, J. E., Theveniau, M. A., Bashirzadeh, R., Reisine, T., and Eden, P. A. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides, 15: 1229-1236, 1994.
13. Tatoud, R., Degeorges, A., Prevost, G., Hoepffner, J. L., Gauville, C., Millot, G., Thomas, F., and Calvo, F. Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro inhibitory effect of BIM-23014 analog. Mol. Cell. Endocrinol., 113: 195-204, 1995.
14. Srkalovic, G., Cai, R. Z., and Schally, A. V. Evaluation of receptors for somatostatin in various tumors using different analogs. J. Clin. Endocrinol. Metab., 70: 661-669, 1990.
15. Weckbecker, G., Raulf, F., Stolz, B., and Bruns, C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther., 60: 245-264, 1993.
16. Pollak, M. N., and Schally, A. V. Mechanism of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med., 217: 143-152, 1998.
17. Patel, Y. C., Greenwood, M. T., Panetta, R., Demchyshyn, L., Niznik, H., and Srikant, S. B. The somatostatin receptor family. Life Sci., 57: 1249-1265, 1995.
18. Reubi, J. C., Waser, B., Schaer, J-C., and Markwalder, R. Somatostatin receptors in human prostate and prostate cancer. J. Clin. Endocrinol. Metab., 80: 2806-2814, 1995.
19. 1]-octreotide scintigraphy. Cancer Res., 55 (Suppl. 23): 5805s-5810s, 1995.
20. Pinski, J., Halmos, G., and Schally, A. V. Somatostatin analog RC-160 and bombesin/ gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett., 71: 189-196, 1993.
21. Pinski, J., Schally, A. V., Halmos, G., and Szepeshàzi, K. Effect of somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer, 55: 963-967, 1993.
22. Yano, T., Pinski, J., Szepeshàzi, K., Milovanovic, S. R., Groot, K., and Schally, A. V. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Prostate, 20: 297-310, 1992.
23. Schally, A. V. Oncological applications of somatostatin analogues. Cancer Res., 48: 6977-6985, 1988.
24. Pinski, J., Reile, H., Halmos, G., Groot, K., and Schally, A. V. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res., 54: 169-174, 1994.
25. Gonzales-Barcena, D., Molina-Ayala, M. A., Cortez-Moralez, A., Vadillo-Buenfil, I., Cardenas-Cornejo, I., Comaru-Schally, A. M., and Schally, A. V. Response to administration of somatostatin analog RC-160 (Vapreotide) in patients with advanced prostatic cancer at relapse time, p. 421. 80th Annual Meeting of the Endocrine Society, New Orleans, LA, June 24-27, 1998.
26. Maulard, C., Richaud, P., Droz, J. P., Jessueld, D., Dufour-Esquerre, F., and Housset, M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chem. Pharmacol., 36: 259-262, 1995.
27. 1]octreotide. Eur. J. Nucl. Med., 21: 328-335, 1994.
28. 1]octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci., 49: 1593-1601, 1991.
29. 3]octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 20: 716-731, 1993.
30. Radulovic, S., Nagy, A., Szoke, B., and Schally, A. V. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett., 62: 263-271, 1992.
31. Nagy, A., Schally, A. V., Halmos, G., Armatis, P., Cai, R. Z., Csernus, V., Kovács, M., Koppán, M., Szepesházi, K., and Kahán, Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA, 95: 1794-1799, 1998.
32. Cai, R. Z., Szoke, B., Lu, R., Fu, D., Redding, T. W., and Schally, A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA, 83: 1896-1900, 1986.
33. Nagy, A., Armatis, P., and Schally A. V. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc. Natl. Acad. Sci. USA, 93: 2464-2469, 1996.
34. Creskoff, A. J., Fitz-Hugh, T., Jr., and Farris, E. J. Hematology of the rat: methods and standards. In: E. J. Farris and J. Q. Griffiths (eds.), The Rat in Laboratory Investigation, pp. 406-420. Philadelphia: J. B. Lippincott Co., 1949.
35. Munson, P. J., and Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Anal. Biochem., 107: 220-239, 1980.
36. McPherson, G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J. Pharmacol. Methods, 14: 213-228, 1985.
37. Kluxen, F. K., Bruns, C., and Lubert, H. Expression cloning of a rat brain somatostatin receptor cDNA. Proc. Natl. Acad. Sci. USA, 89: 4618-4622, 1992.
38. O'Carrol, A. M., Lolait, S. J., Konig, M., and Mahan, L. C. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol. Pharmacol., 42: 939-946, 1992.
39. Murata, T., Takizawa, T., Funaba, M., Fujimura, H., Murata, E., and Torii, K. Quantitation of mouse and rat β-actin mRNA by competitive polymerase chain reaction using capillary electrophoresis. Anal. Biochem., 244: 172-174, 1997.
40. Steel, R. G., and Torrie, J. Principles and Procedures of Statistics, p. 114. New York: McGraw-Hill, Inc., 1976.
41. Isaacs, J. T. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas. Cancer Res., 42: 5010-5014, 1982.
42. Ripamonti, M., Pezzoni, G., Pesenti, E., Pastori, A., Farao, M., Bargiotti, A., Suarato, A., Spreafico, F., and Grandi, M. In vivo anti-tumor activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Br. J. Cancer, 65: 703-707, 1992.
43. Stolz, B., Smith-Jones, P., Albert, R., Tolcsvai, L., Briner, U., Ruser, G., Mäcke, H., Weckbecker, G., and Bruns, C. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion, 57 (Suppl. 1); 17-21, 1996.
44. Wiseman, G. A., and Kvols, L. K. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. Nucl. Med., 25: 272-278, 1995.
45. Otte, A., Mueller-Brand, J., Dellas, S., Nitsche, E. U., Herrmann, R., and Maecke, H. R. Yttrium-90-labeled somatostatin-analogue for cancer treatment. Lancet, 351: 417-418, 1998.